嵌合抗原受体在宫颈癌治疗中的研究进展  

Research progress of chimeric antigen receptor in treatment of cervical cancer

作　　者：蒋嘉仪 王亮[2] JIANG Jia-yi;WANG Liang(Fujian Medical University,Fuzhou FUJIAN 350122,China;College of Clinical Medicine for Obstetrics&Gynecology and Pediatrics(Fujian Provincial Maternity and Children’s Hospital),Fujian Medical University,Fuzhou FUJIAN 350001,China)

机构地区：[1]福建医科大学,福建福州350122 [2]福建医科大学妇儿临床医学院(福建省妇幼保健院),福建福州350001

出　　处：《中国新药与临床杂志》2025年第3期175-180,共6页Chinese Journal of New Drugs and Clinical Remedies

基　　金：国家自然科学基金(82303734)。

摘　　要：宫颈癌为女性生殖系统常见恶性肿瘤,近年来呈现出年轻化发展趋势,严重威胁女性健康,大部分宫颈癌与人乳头状瘤病毒(HPV)感染相关。早期宫颈癌可通过传统的手术治疗、化疗和放疗进行干预且疗效显著。然而,对于晚期、复发性或转移性宫颈癌,传统治疗手段的疗效欠佳。现阶段,免疫治疗已成为宫颈癌治疗的重要研究方向之一,过继性细胞免疫疗法中嵌合抗原受体(CAR)-T细胞疗法、CAR-自然杀伤(NK)细胞疗法在妇科恶性肿瘤治疗领域已取得了突破性的进展。本文总结了近年来CAR疗法在宫颈癌免疫治疗上的重要研究进展,系统性地讨论了以CAR-T和CAR-NK为代表的细胞疗法的现状和局限性,对宫颈癌免疫治疗的研究进展、面临的挑战及治疗潜在靶点进行综述。Cervical cancer is a common malignant tumor of the female reproductive system.In recent years,it has shown a trend of younger development,which seriously threatens women’s health.Most cervical cancer is related to HPV infection.Early-stage cervical cancer can be effectively managed through traditional surgical intervention,chemotherapy and radiotherapy,demonstrating favorable clinical outcome.However,current treatment modalities exhibit limited efficacy in advanced,recurrent,or metastatic cervical cancer.At present,immunotherapy has become one of the important research directions in the treatment of cervical cancer.Adoptive cell immunotherapy,particularly chimeric antigen receptor(CAR)-T cell therapy and CAR natural killer(NK)-cell therapy have made breakthrough progress in the treatment of gynecological malignant tumors.This article reviewed the important research progress of CAR therapy in the immunotherapy of cervical cancer in recent years and systematically discussed the current status and limitations of cell therapy represented by CAR-T and CAR-NK,covering the research status,challenges faced,and potential therapeutic targets for cervical cancer.

关 键 词：嵌合抗原受体 宫颈癌 免疫治疗 人乳头状瘤病毒 

分 类 号：R737.33[医药卫生—肿瘤]